The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Chemotherapy Induced Peripheral Neuropathy Treatment Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The chemotherapy induced peripheral neuropathy treatment market size has shown significant growth in recent years. This market is anticipated to expand from $1.75 billion in 2025 to $1.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. Historically, this growth can be ascribed to the increasing utilization of neurotoxic chemotherapy agents, rising cancer survival rates, growing acknowledgment of chemotherapy side effects, the availability of symptomatic treatment options, and the expansion of oncology care infrastructure.

The market for chemotherapy induced peripheral neuropathy treatment is projected to experience robust expansion over the coming years. This market is anticipated to reach $2.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated expansion during the forecast period stems from greater investment in targeted neuropathy treatments, a heightened emphasis on individualized oncology supportive care, an increase in clinical trials for CIPN medications, an escalating need for therapies that enhance quality of life, and progress in biomarker-driven diagnostics. Key trends observed within this period encompass an elevated focus on developing neuroprotective drugs, a greater uptake of combination therapy methods, a stronger emphasis on prompt diagnosis and symptom control, the broadening of personalized treatment plans, and intensified clinical investigations into CIPN management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

The chemotherapy-induced peripheral neuropathy treatment market is anticipated to expand due to the escalating incidence of cancer. Cancer is defined as a condition involving the unchecked proliferation and spread of abnormal cells throughout the body. Chemotherapy-induced peripheral neuropathy itself is a potential adverse effect associated with certain chemotherapy medications utilized in cancer treatment. The market for treating chemotherapy-induced peripheral neuropathy is set for growth, driven by the global surge in cancer diagnoses. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which equates to over 450 cases daily, with males making up approximately 55% of these diagnoses. Thus, the rising occurrence of cancers is a primary driver for the chemotherapy-induced peripheral neuropathy treatment market’s advancement.

What Major Segment Divisions Exist Within The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes

2) By Treatment: Medication, Therapy, Other Treatments

3) By Drug Type: Branded, Generic

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Research Institutes, Specialty Clinics

Subsegments:

1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine

2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine

4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10

5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies

Which Trends Are Impacting The Growth Of The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

Leading firms within the chemotherapy-induced peripheral neuropathy treatment market are concentrating on developing novel products to enhance their detection capabilities and maintain their competitive standing. For example, AlgoTx, a clinical-stage firm focused on managing complex pain, announced in March 2023 that the FDA had approved the Investigational New Drug Application (IND) for ATX01, its unique Phase 2 candidate. This novel therapy is designed for patients suffering from erythromelalgia. Concurrently, initial patients have been randomized into the ATX01 for the Pain of Chemotherapy (ACT) study, which addresses chemotherapy-induced peripheral neuropathy (CIPN). Both initiatives have been granted fast-track designation by the FDA.

Which Companies Are Leading Innovation In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.

Read the full chemotherapy induced peripheral neuropathy treatment market report here:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

What Are The Leading Geographic Regions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11967&type=smp

Browse Through More Reports Similar to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2026, By The Business Research Company

Chemotherapy Global Market Report

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Cancer Supportive Care Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model